BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Treatment of WT- and T315I-BCR-ABL-expressing CML cells by niclosamide diminished such a enrichment of Sp1, and decreased WT- and T315I-BCR-ABL transcription and its downstream signaling molecules such as STAT5 and Akt.